A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Protocol – ECOG – EA6192 SCHEMA EA6192 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Must be at least 18 years of age. Patient must have active advanced melanoma, defined as unresectable stage IIIB-IV by AJCC 8th […]
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim Versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Protocol: ECOG – EA6141 SCHEMA EA6141 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Must be at least 18 years of age. ECOG Performance Status 0-1 Patients must have known BRAF mutational status of tumor; Wildtype (WT) […]